Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: the stated indication (hyperkalemia in adults and pediatric patients ≥12 years) and the limitation against emergency life-threatening hyperkalemia are supported by the label excerpts provided. However, several other claims are either incorrectly specific (hemodialysis-only) or are not supported by the provided label sections (e.g., magnesium/calcium/sodium statements and patent-related assertions).
Category Scores
Accurate Statements
Veltassa is a medication used to treat hyperkalemia (high potassium levels) in adults undergoing dialysis.
Not supported as stated (hemodialysis/dialysis-only specificity not present in provided label excerpts).
Veltassa is a potassium-binding polymer.
Supported indirectly: provided description/mechanism states it is a non-absorbed potassium-binding polymer (11 DESCRIPTION/12.1).
Veltassa binds to potassium ions in the digestive tract.
Supported: 12.1 Mechanism of Action: “increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract.”
Veltassa prevents potassium from being absorbed into the bloodstream.
Partially supported: 12.1 states binding “reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.” It does not explicitly say “prevents…from being absorbed into the bloodstream.”
Veltassa allows excess potassium to be excreted in the stool.
Supported: 12.1 states “increases fecal potassium excretion” and binding leads to reduction in serum potassium.
Veltassa helps to lower potassium levels in the blood.
Supported: 12.1: “resulting in a reduction of serum potassium levels.”
Veltassa can be taken orally.
Supported: 11 DESCRIPTION: “powder for suspension in water for oral administration.”
The patent for Veltassa expires in 2029.
Not supported by provided prescribing information excerpts.
Veltassa is indicated for the treatment of hyperkalemia in adults undergoing dialysis.
Not supported as stated (dialysis/hemodialysis limitation not present in provided label excerpts).
Veltassa is specifically approved for use in adults undergoing hemodialysis.
Not supported by provided label excerpts; label excerpt states indication includes adults and pediatric patients ≥12 years (not dialysis-specific).
Unsupported Statements
Veltassa is a medication used to treat hyperkalemia (high potassium levels) in adults undergoing dialysis.
Provided label excerpt for Indications/Usage does not state dialysis/hemodialysis-specific approval; it states hyperkalemia in adults and pediatric patients ages 12 years and older.
Veltassa does not affect magnesium levels in the blood.
Contradicted by label excerpt: Veltassa can bind magnesium and lead to hypomagnesemia; monitor serum magnesium.
Veltassa does not affect calcium levels in the blood.
No such statement appears in provided label excerpts.
Veltassa does not affect sodium levels in the blood.
No such statement appears in provided label excerpts.
Veltassa is specifically approved for use in adults undergoing hemodialysis.
Provided label excerpt does not limit indication to hemodialysis; it includes adults and pediatric patients ≥12 years.
Veltassa is available by prescription only.
No such statement appears in provided label excerpts.
The patent for Veltassa is owned by the manufacturer, Relypsa.
No patent ownership statement appears in provided label excerpts.
The patent for Veltassa expires in 2029.
No patent expiry statement appears in provided label excerpts.
Contradictions
High
AI Statement
Veltassa does not affect magnesium levels in the blood.
Label Reference
5 WARNINGS AND PRECAUTIONS (5.2) Hypomagnesemia: “Veltassa binds to magnesium in the colon, which can lead to hypomagnesemia… Monitor serum magnesium.”
Important Omissions
Dose/administration details (e.g., dosing frequency, preparation/administration instructions, timing with other oral medications such as administering other oral medications at least 3 hours before or after Veltassa).
Importance:
Moderate
Limitation of use that it should not be used for life-threatening hyperkalemia due to delayed onset of action.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A contradictory claim was made regarding magnesium: the label warns Veltassa can lead to hypomagnesemia and recommends monitoring serum magnesium.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect dialysis/hemodialysis specificity and a direct contradiction regarding magnesium levels; several statements are unsupported by the provided label excerpts (including patent and product-label regulatory claims).
Suggested Improvement
Use only label-supported wording: state indication as hyperkalemia in adults and pediatric patients ≥12 years; include the limitation against emergency life-threatening hyperkalemia; remove or correct the magnesium claim and any unsupported calcium/sodium/prescription/patent statements.